{"id":10591,"date":"2025-10-22T13:52:30","date_gmt":"2025-10-22T18:52:30","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=10591"},"modified":"2025-10-22T13:52:32","modified_gmt":"2025-10-22T18:52:32","slug":"sars-cov-2-mrna-vaccines-sensitize-tumours-to-immune-checkpoint-blockade","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2025\/10\/22\/sars-cov-2-mrna-vaccines-sensitize-tumours-to-immune-checkpoint-blockade\/","title":{"rendered":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y\">Nature<\/a><\/p>\n\n\n\n<p>Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity<sup><a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR1\">1<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR2\">2<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR3\">3<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR4\">4<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR5\">5<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR6\">6<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR7\">7<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR8\">8<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR9\">9<\/a><\/sup>. Although personalized mRNA cancer vaccines sensitize tumours to ICIs by directing immune attacks against preselected antigens, personalized vaccines are limited by complex and time-intensive manufacturing processes<sup><a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR10\">10<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR11\">11<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR12\">12<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR13\">13<\/a>,<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09655-y#ref-CR14\">14<\/a><\/sup>. Here we show that mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to ICIs. In preclinical models, SARS-CoV-2 mRNA vaccines led to a substantial increase in type I interferon, enabling innate immune cells to prime CD8<sup>+<\/sup>\u00a0T cells that target tumour-associated antigens.\u00a0<\/p>\n<a rel=\"nofollow\" href=\"\/secure-location.php\" style=\"display: none;\" title=\"PhXIyoY qTZ tY\"><!-- PhXIyoY qTZ tY --><\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Nature Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity1,2,3,4,5,6,7,8,9. Although personalized mRNA cancer vaccines sensitize tumours to ICIs by directing immune attacks against preselected antigens, personalized vaccines are limited by complex and time-intensive manufacturing processes10,11,12,13,14. Here we show that mRNA vaccines targeting SARS-CoV-2 also [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[16,8],"tags":[],"class_list":["post-10591","post","type-post","status-publish","format-standard","hentry","category-published-research","category-vaccine-headlines"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/10591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=10591"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/10591\/revisions"}],"predecessor-version":[{"id":10592,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/10591\/revisions\/10592"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=10591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=10591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=10591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}